[go: up one dir, main page]

CR8094A - Derivados de imidazol antagonistas del receptor de glutamato - Google Patents

Derivados de imidazol antagonistas del receptor de glutamato

Info

Publication number
CR8094A
CR8094A CR8094A CR8094A CR8094A CR 8094 A CR8094 A CR 8094A CR 8094 A CR8094 A CR 8094A CR 8094 A CR8094 A CR 8094A CR 8094 A CR8094 A CR 8094A
Authority
CR
Costa Rica
Prior art keywords
antagonists
imidazol derivatives
glutamate
receiver
derivatives antagonists
Prior art date
Application number
CR8094A
Other languages
English (en)
Inventor
Bernd Buettelmann
Simona Maria Ceccarelli
Georg Jaeschke
Richard Hugh Philip Porter
Eric Vieira
Sabine Kolczewski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR8094A publication Critical patent/CR8094A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a derivados del imidazol que son antagonistas del receptor mGluR5, los cuales estan representados por la formula general I, en donde R1, R2, R3 y R4 son como se han definido en la especificacion, a un procedimiento para la obtencion de los mismos, asi como tambien a las sales farmaceuticamente aceptables de los mismos para la elaboracion de un medicamento para el tratamiento o la prevencion de trastornos inducidos por el receptor mGLUR5, tales como trastornos neurologicos agudos y/o cronicos.
CR8094A 2003-06-05 2005-11-14 Derivados de imidazol antagonistas del receptor de glutamato CR8094A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03012200 2003-06-05

Publications (1)

Publication Number Publication Date
CR8094A true CR8094A (es) 2006-05-30

Family

ID=33483899

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8094A CR8094A (es) 2003-06-05 2005-11-14 Derivados de imidazol antagonistas del receptor de glutamato

Country Status (38)

Country Link
US (3) US7332510B2 (es)
EP (1) EP1636206B1 (es)
JP (1) JP4401384B2 (es)
KR (1) KR100778948B1 (es)
CN (1) CN100408572C (es)
AR (1) AR044478A1 (es)
AT (1) ATE377008T1 (es)
AU (1) AU2004245208B2 (es)
BR (1) BRPI0411095B8 (es)
CA (1) CA2527315C (es)
CL (1) CL2004001347A1 (es)
CR (1) CR8094A (es)
CY (1) CY1107856T1 (es)
DE (1) DE602004009796T2 (es)
DK (1) DK1636206T3 (es)
EA (1) EA010577B1 (es)
EC (1) ECSP056202A (es)
ES (1) ES2294504T3 (es)
GT (1) GT200400117A (es)
HN (1) HN2004000208A (es)
HR (1) HRP20070529T3 (es)
IL (1) IL171930A (es)
MA (1) MA27881A1 (es)
MX (1) MXPA05013149A (es)
MY (2) MY137272A (es)
NO (1) NO332143B1 (es)
NZ (1) NZ543637A (es)
PA (1) PA8604101A1 (es)
PE (1) PE20050162A1 (es)
PL (1) PL1636206T3 (es)
PT (1) PT1636206E (es)
RS (1) RS53183B (es)
SI (1) SI1636206T1 (es)
TN (2) TNSN05309A1 (es)
TW (1) TWI338007B (es)
UA (1) UA80888C2 (es)
WO (1) WO2004108701A1 (es)
ZA (2) ZA200509807B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7452909B2 (en) 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
HRP20080363T3 (hr) * 2004-06-01 2008-09-30 F. Hoffmann - La Roche Ag Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
CN101568531B (zh) * 2006-12-21 2013-11-13 弗·哈夫曼-拉罗切有限公司 Mglur5受体拮抗剂的多晶型物
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
BR112013023813A2 (pt) 2011-03-18 2016-12-13 Novartis Ag combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson
EP2909180B1 (en) * 2012-10-18 2016-10-05 F. Hoffmann-La Roche AG Ethynyl derivatives as modulators of mglur5 receptor activity
NZ703537A (en) * 2012-10-18 2018-06-29 Hoffmann La Roche Ethynyl derivatives
BR112018069868A2 (pt) * 2016-03-30 2019-01-29 Sinntaxis AB modulador alostérico negativo do receptor metabotrópico de glutamato 5, usos de um nam, e método de tratamento ou atenuação de dano cerebral maduro
JP2023504177A (ja) * 2019-12-02 2023-02-01 エフ.ホフマン-ラ ロシュ アーゲー アルキニル-(ヘテロアリール)-カルボキサミドhcn1阻害剤
EP4161512A1 (en) 2020-06-05 2023-04-12 Noema Pharma AG Methods of treatment of tuberous sclerosis complex
MX2023001288A (es) 2020-07-30 2023-04-28 Noema Pharma Ag Metodos de tratamiento de la neuralgia del trigemino.
EP4658268A1 (en) 2023-02-02 2025-12-10 Noema Pharma AG Methods of treatment of dravet syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508560A (en) * 1981-11-11 1985-04-02 Ciba Geigy Corporation Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
AU780009B2 (en) * 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
JP5154728B2 (ja) * 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ,インコーポレイテッド 神経栄養活性を有する置換5−アルキニルピリミジン
HUP0400570A3 (en) * 2000-12-04 2004-09-28 Hoffmann La Roche Phenylethenyl or phenylethinyl heteroaril derivatives as glutamate receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
AU2002360621B2 (en) * 2001-12-19 2007-01-25 Merck & Co., Inc. heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
JP2006513996A (ja) * 2002-10-24 2006-04-27 メルク エンド カムパニー インコーポレーテッド 代謝調節型グルタミン酸受容体結合用トレーサーとしてのアルキン誘導体
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7091222B2 (en) * 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives

Also Published As

Publication number Publication date
WO2004108701A1 (en) 2004-12-16
SI1636206T1 (sl) 2008-02-29
PL1636206T3 (pl) 2008-04-30
PT1636206E (pt) 2008-01-28
AU2004245208A1 (en) 2004-12-16
EP1636206B1 (en) 2007-10-31
DE602004009796T2 (de) 2008-08-28
BRPI0411095B8 (pt) 2021-05-25
PE20050162A1 (es) 2005-03-22
MY137272A (en) 2009-01-30
TW200509920A (en) 2005-03-16
HN2004000208A (es) 2009-02-03
CY1107856T1 (el) 2013-06-19
HK1093070A1 (zh) 2007-02-23
BRPI0411095B1 (pt) 2018-04-03
DE602004009796D1 (de) 2007-12-13
ES2294504T3 (es) 2008-04-01
TNSN06391A1 (fr) 2008-02-22
GT200400117A (es) 2005-02-07
IL171930A0 (en) 2006-04-10
CA2527315A1 (en) 2004-12-16
NO332143B1 (no) 2012-07-02
EP1636206A1 (en) 2006-03-22
ZA200609681B (en) 2008-06-25
AU2004245208B2 (en) 2007-04-26
ZA200509807B (en) 2006-12-27
ATE377008T1 (de) 2007-11-15
US20080119489A1 (en) 2008-05-22
HRP20070529T3 (hr) 2008-05-31
CN100408572C (zh) 2008-08-06
MXPA05013149A (es) 2006-03-17
RS20050892A (sr) 2007-12-31
ECSP056202A (es) 2006-04-19
KR100778948B1 (ko) 2007-11-28
EA010577B1 (ru) 2008-10-30
JP2006526588A (ja) 2006-11-24
US7332510B2 (en) 2008-02-19
UA80888C2 (en) 2007-11-12
AR044478A1 (es) 2005-09-14
US20040248888A1 (en) 2004-12-09
US8481548B2 (en) 2013-07-09
TWI338007B (en) 2011-03-01
IL171930A (en) 2010-12-30
DK1636206T3 (da) 2008-02-11
EA200501887A1 (ru) 2006-10-27
JP4401384B2 (ja) 2010-01-20
BRPI0411095A (pt) 2006-07-18
KR20060057537A (ko) 2006-05-26
US20080103306A1 (en) 2008-05-01
NZ543637A (en) 2008-04-30
CL2004001347A1 (es) 2005-05-06
NO20055465L (no) 2005-11-18
TNSN05309A1 (fr) 2007-07-10
MA27881A1 (fr) 2006-05-02
RS53183B (sr) 2014-06-30
US7973165B2 (en) 2011-07-05
CN1802367A (zh) 2006-07-12
CA2527315C (en) 2010-08-10
PA8604101A1 (es) 2004-12-16
MY143353A (en) 2011-04-29

Similar Documents

Publication Publication Date Title
CR8094A (es) Derivados de imidazol antagonistas del receptor de glutamato
CY1120258T1 (el) Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος
UY28833A1 (es) Piridonas sustituidas como inhibidores de poli (adp-ribosa)-polimerasa (parp).
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
DOP2009000258A (es) Compuestos amino-heterociclicos
MX2012004848A (es) Compuestos heterociclicos triciclicos.
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
GT200800033A (es) Antagonistas de los receptores 2 de dopamina de rapida disociacion
UY28144A1 (es) Agentes terapéuticos
NO20085099L (no) Puritonderivativer som HM74A agonister
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
DE602005023197D1 (de) -muscarinrezeptors
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY30577A1 (es) Derivados de éter diarilico y usos de los mismos
UY30706A1 (es) Diaril, dipiridinil y arilpiridinil derivados y usos de los mismos
CR9436A (es) Derivados de aril 1,4-pirazina sustituidos
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
UY28839A1 (es) Agentes terapeuticos
UY27544A1 (es) Derivados de piperazina desestabilizantes del receptor de andrógenos
DOP2004000920A (es) Derivados de imidazol como antagonistas de receptor de glutamato
PL1732902T3 (pl) Pochodne nukleozydów i ich terapeutyczne zastosowanie